Waters Valuation
Is WAT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of WAT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: WAT * (MX$7620) is trading above our estimate of fair value (MX$7059.53)
Significantly Below Fair Value: WAT * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WAT *?
Key metric: As WAT * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is WAT *'s PE Ratio? | |
|---|---|
| PE Ratio | 34.1x |
| Earnings | US$622.64m |
| Market Cap | US$21.24b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.9x |
| Enterprise Value/EBITDA | 22.7x |
| PEG Ratio | 4x |
Price to Earnings Ratio vs Peers
How does WAT *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 66.7x | ||
WST West Pharmaceutical Services | 46.5x | 12.7% | US$22.6b |
MTD Mettler-Toledo International | 31.7x | 7.6% | US$24.6b |
DIVISLAB Divi's Laboratories | 86.4x | 23.7% | ₹1.6t |
DIM Sartorius Stedim Biotech | 102.2x | 31.9% | €16.4b |
WAT * Waters | 34.1x | 8.6% | Mex$21.2b |
Price-To-Earnings vs Peers: WAT * is good value based on its Price-To-Earnings Ratio (34.1x) compared to the peer average (66.1x).
Price to Earnings Ratio vs Industry
How does WAT *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: WAT * is expensive based on its Price-To-Earnings Ratio (34.1x) compared to the Global Life Sciences industry average (33.6x).
Price to Earnings Ratio vs Fair Ratio
What is WAT *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 34.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate WAT *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | Mex$7,553.05 0% | 7.5% | Mex$8,348.60 | Mex$6,538.06 | n/a | 17 |
| Nov ’25 | Mex$6,516.00 | Mex$7,302.82 +12.1% | 7.0% | Mex$8,414.79 | Mex$6,589.90 | n/a | 17 |
| Oct ’25 | Mex$6,637.00 | Mex$6,695.85 +0.9% | 6.7% | Mex$7,453.02 | Mex$5,883.96 | n/a | 17 |
| Sep ’25 | Mex$6,501.00 | Mex$6,703.98 +3.1% | 6.7% | Mex$7,487.86 | Mex$5,911.47 | n/a | 17 |
| Aug ’25 | Mex$6,050.00 | Mex$6,339.95 +4.8% | 6.3% | Mex$7,039.54 | Mex$5,631.63 | n/a | 16 |
| Jul ’25 | Mex$5,168.00 | Mex$5,967.86 +15.5% | 5.7% | Mex$6,591.35 | Mex$5,063.19 | n/a | 16 |
| Jun ’25 | Mex$5,575.00 | Mex$5,434.40 -2.5% | 4.8% | Mex$5,967.65 | Mex$4,917.47 | n/a | 16 |
| May ’25 | Mex$5,329.00 | Mex$5,575.13 +4.6% | 4.9% | Mex$5,997.29 | Mex$5,140.53 | n/a | 17 |
| Apr ’25 | n/a | Mex$5,516.32 0% | 4.8% | Mex$5,968.20 | Mex$5,115.60 | n/a | 16 |
| Mar ’25 | n/a | Mex$5,516.32 0% | 4.8% | Mex$5,968.20 | Mex$5,115.60 | n/a | 16 |
| Feb ’25 | n/a | Mex$5,157.60 0% | 8.2% | Mex$5,967.60 | Mex$4,305.63 | n/a | 16 |
| Jan ’25 | n/a | Mex$4,824.68 0% | 10.4% | Mex$5,948.68 | Mex$3,948.62 | n/a | 17 |
| Dec ’24 | Mex$4,750.11 | Mex$4,786.25 +0.8% | 8.7% | Mex$5,682.44 | Mex$4,046.32 | n/a | 17 |
| Nov ’24 | n/a | Mex$5,252.63 0% | 6.1% | Mex$5,867.00 | Mex$4,722.67 | Mex$6,516.00 | 17 |
| Oct ’24 | n/a | Mex$5,257.27 0% | 5.2% | Mex$5,845.88 | Mex$4,739.90 | Mex$6,637.00 | 17 |
| Sep ’24 | n/a | Mex$5,151.21 0% | 4.5% | Mex$5,663.43 | Mex$4,677.01 | Mex$6,501.00 | 17 |
| Aug ’24 | n/a | Mex$4,964.62 0% | 5.8% | Mex$5,441.93 | Mex$4,520.99 | Mex$6,050.00 | 17 |
| Jul ’24 | n/a | Mex$5,296.78 0% | 7.4% | Mex$6,423.98 | Mex$4,796.57 | Mex$5,168.00 | 17 |
| Jun ’24 | n/a | Mex$5,540.01 0% | 7.3% | Mex$6,633.15 | Mex$4,952.75 | Mex$5,575.00 | 17 |
| May ’24 | n/a | Mex$6,296.60 0% | 5.9% | Mex$6,864.26 | Mex$5,111.68 | Mex$5,329.00 | 17 |
| Apr ’24 | n/a | Mex$6,343.13 0% | 6.6% | Mex$6,979.93 | Mex$5,076.32 | n/a | 16 |
| Mar ’24 | n/a | Mex$6,401.87 0% | 6.6% | Mex$7,078.46 | Mex$5,147.97 | n/a | 15 |
| Feb ’24 | Mex$6,610.88 | Mex$6,439.69 -2.6% | 7.3% | Mex$7,155.21 | Mex$5,272.26 | n/a | 16 |
| Jan ’24 | n/a | Mex$6,528.97 0% | 6.7% | Mex$7,344.48 | Mex$5,469.30 | n/a | 16 |
| Dec ’23 | n/a | Mex$6,558.18 0% | 6.8% | Mex$7,400.58 | Mex$5,511.07 | Mex$4,750.11 | 15 |
| Nov ’23 | n/a | Mex$6,625.89 0% | 7.5% | Mex$7,454.12 | Mex$5,521.57 | n/a | 15 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
IQVIA Holdings
US$34.7b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV *
US$3,880.00
7D
-11.8%
1Y
12.0%
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
ROVI N
€1,416.38
7D
0%
1Y
54.7%
ICON
US$16.8b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
0%
1Y
-7.7%